Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study

Gray, Ronan T.; Coleman, Helen G.; Hughes, Carmel; Murray, Liam J.; Cardwell, Chris R.

doi:10.1186/s12885-018-4142-y

BMC Cancer

Table 3 Sensitivity analyses for the association between aspirin use and CRC-specific survival in patients with colorectal cancer

From: Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study

	Aspirin user			Aspirin non-user
	Mortality	Patients	Person years	Mortality	Patients	Person years	Unadjusted HR (95% CI)	P value	Adjusted HR (95% CI)	P value
CRC-specific survival
Post-diagnostic aspirin use (fixed time exposure in first year)^a
Aspirin user vs. non-user	310	2150	5692	754	6241	16,442	1.19 (1.05, 1.36)	0.01	1.10 (0.94, 1.29)	0.22
Post-diagnostic aspirin use versus non-use stratified by pre-diagnostic use (excludes 2009 cases)^b
Pre-diagnostic users	168	1333	2983	46	257	614	0.75 (0.54,1.04)	0.08	0.80 (0.56,1.13)	0.20
Pre-diagnostic non-users	51	435	744	467	4301	9930	1.52 (1.13,2.03)	0.01	1.51 (1.12,2.05)	0.01
Aspirin use vs. non-use in year before colorectal cancer diagnosis (excludes 2009 cases)^c
Aspirin user vs. non-user	1104	2853	6460	2551	7555	18,652	1.23 (1.14, 1.32)	< 0.001	0.96 (0.88, 1.05)	0.37

Abbreviations: CI confidence interval, CRC colorectal cancer, HR hazard ratio
^aModel contains age, sex, year of diagnosis, deprivation, site (colon or rectum), stage, grade, cancer treatment within six months (radiotherapy, chemotherapy, surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and statin use (in first year after diagnosis)
^bExcluding patients diagnosed in 2009 (who do not have complete prescription records for year before diagnosis). Based upon main time-varying covariate multivariable model containing age, sex, year of diagnosis, deprivation, site (colon or rectum), stage, grade, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and statin use (as time-varying covariate)
^cExcluding patients diagnosed in 2009 (who do not have complete prescription records for year before diagnosis) but not excluding patients who die within 1 year of diagnosis; adjusted model contains age, sex, year of diagnosis, deprivation, site (colon or rectum), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and statin use (in year prior to diagnosis)

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com